AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Perspectives
This section features opinion pieces, reflections, and expert commentary on timely or overlooked issues in cancer care, research, and the oncology workforce.
"I Think of Myself as a Plumber": The Engineer Trying to Fix Global Diagnostic Inequity
By Ariana Sutherland
"I think of myself as a plumber by training," Ayokunle Olanrewaju, PhD, says to a room of oncology healthcare providers.
"I Think of Myself as a Plumber": The Engineer Trying to Fix Global Diagnostic Inequity
By Ariana Sutherland
"I think of myself as a plumber by training," Ayokunle Olanrewaju, PhD, says to a room of oncology healthcare providers.
"I Think of Myself as a Plumber": The Engineer Trying to Fix Global Diagnostic Inequity
By Ariana Sutherland
"I think of myself as a plumber by training," Ayokunle Olanrewaju, PhD, says to a room of oncology healthcare providers.
Mantle Cell Lymphoma in 2026: Auto-Transplant's Role Is fading, BTKi Combinations Are Frontline, and Brexu-cel Has Five-Year Data in RR-MCL
By Preetesh Jain, MD, DM, PhD
Mantle cell lymphoma is biologically diverse, clinically unpredictable, and historically difficult to treat with sustained efficacy.
Mantle Cell Lymphoma in 2026: Auto-Transplant's Role Is fading, BTKi Combinations Are Frontline, and Brexu-cel Has Five-Year Data in RR-MCL
By Preetesh Jain, MD, DM, PhD
Mantle cell lymphoma is biologically diverse, clinically unpredictable, and historically difficult to treat with sustained efficacy.
Mantle Cell Lymphoma in 2026: Auto-Transplant's Role Is fading, BTKi Combinations Are Frontline, and Brexu-cel Has Five-Year Data in RR-MCL
By Preetesh Jain, MD, DM, PhD
Mantle cell lymphoma is biologically diverse, clinically unpredictable, and historically difficult to treat with sustained efficacy.
HER2-Positive Breast Cancer in 2026: TDXd Enters the First Line, Maintenance Gets Smarter, and Early Disease Is Changing Fast with TDxd neoadjuvant and adjuvant approvals
By Dr. Milana Dolezal
The treatment of HER2-positive metastatic breast cancer has undergone more transformation in the past two years than in the prior decade.
HER2-Positive Breast Cancer in 2026: TDXd Enters the First Line, Maintenance Gets Smarter, and Early Disease Is Changing Fast with TDxd neoadjuvant and adjuvant approvals
By Dr. Milana Dolezal
The treatment of HER2-positive metastatic breast cancer has undergone more transformation in the past two years than in the prior decade.
HER2-Positive Breast Cancer in 2026: TDXd Enters the First Line, Maintenance Gets Smarter, and Early Disease Is Changing Fast with TDxd neoadjuvant and adjuvant approvals
By Dr. Milana Dolezal
The treatment of HER2-positive metastatic breast cancer has undergone more transformation in the past two years than in the prior decade.
Prostate Cancer in 2026: Personalizing ADT Duration, PARP Inhibitors Move Earlier, and a Bispecific That May Finally Crack Immunotherapy in This Disease
By Li Zhang, MD
From ADT duration optimization to PARP inhibitors in hormone-sensitive disease and a promising T-cell engager in mCRPC, Dr. Li Zhang maps the shift toward precision in prostate cancer care in 2026.
Prostate Cancer in 2026: Personalizing ADT Duration, PARP Inhibitors Move Earlier, and a Bispecific That May Finally Crack Immunotherapy in This Disease
By Li Zhang, MD
From ADT duration optimization to PARP inhibitors in hormone-sensitive disease and a promising T-cell engager in mCRPC, Dr. Li Zhang maps the shift toward precision in prostate cancer care in 2026.
Prostate Cancer in 2026: Personalizing ADT Duration, PARP Inhibitors Move Earlier, and a Bispecific That May Finally Crack Immunotherapy in This Disease
By Li Zhang, MD
From ADT duration optimization to PARP inhibitors in hormone-sensitive disease and a promising T-cell engager in mCRPC, Dr. Li Zhang maps the shift toward precision in prostate cancer care in 2026.
What Does Oncology Have to Do With Advocacy, Anyway?
By Ariana Sutherland
Ask a room full of oncologists who among them is an advocate, and most hands stay down. Now ask whether they educate patients about their care, push back on insurance denials, or speak up when something is wrong.
What Does Oncology Have to Do With Advocacy, Anyway?
By Ariana Sutherland
Ask a room full of oncologists who among them is an advocate, and most hands stay down. Now ask whether they educate patients about their care, push back on insurance denials, or speak up when something is wrong.
What Does Oncology Have to Do With Advocacy, Anyway?
By Ariana Sutherland
Ask a room full of oncologists who among them is an advocate, and most hands stay down. Now ask whether they educate patients about their care, push back on insurance denials, or speak up when something is wrong.
Asking Because We Care: Why SOGI Data Is Essential to Equitable Cancer Care
By Tiffany Go, MPA, CPCHE
LGBTQ+ patients face real cancer care disparities—and without SOGI data, they remain invisible. A health equity leader at Fred Hutch makes the case for standardized, affirming data collection across cancer care settings.
Asking Because We Care: Why SOGI Data Is Essential to Equitable Cancer Care
By Tiffany Go, MPA, CPCHE
LGBTQ+ patients face real cancer care disparities—and without SOGI data, they remain invisible. A health equity leader at Fred Hutch makes the case for standardized, affirming data collection across cancer care settings.
Asking Because We Care: Why SOGI Data Is Essential to Equitable Cancer Care
By Tiffany Go, MPA, CPCHE
LGBTQ+ patients face real cancer care disparities—and without SOGI data, they remain invisible. A health equity leader at Fred Hutch makes the case for standardized, affirming data collection across cancer care settings.
Triple Negative Breast Cancer in 2026: ADCs Move to the Front, Immunotherapy Stays Central, and Biomarkers Still Lag Behind
By Nikitha Vobugari, MD
ADCs are moving to the front line in metastatic TNBC, immunotherapy's role in early-stage disease is being refined, and biomarkers still lag behind. Dr. Nikitha Vobugari breaks down where the field stands in 2026.
Triple Negative Breast Cancer in 2026: ADCs Move to the Front, Immunotherapy Stays Central, and Biomarkers Still Lag Behind
By Nikitha Vobugari, MD
ADCs are moving to the front line in metastatic TNBC, immunotherapy's role in early-stage disease is being refined, and biomarkers still lag behind. Dr. Nikitha Vobugari breaks down where the field stands in 2026.
Triple Negative Breast Cancer in 2026: ADCs Move to the Front, Immunotherapy Stays Central, and Biomarkers Still Lag Behind
By Nikitha Vobugari, MD
ADCs are moving to the front line in metastatic TNBC, immunotherapy's role in early-stage disease is being refined, and biomarkers still lag behind. Dr. Nikitha Vobugari breaks down where the field stands in 2026.
CAR-T or Bispecific Antibodies First? A Practical Sequencing Guide for Relapsed Multiple Myeloma in 2026
By Sean Maximillian Taasan, MD
CAR-T or bispecific antibodies first? A myeloma specialist breaks down the sequencing evidence, IMWG guidance, and practical factors that should guide treatment decisions in relapsed multiple myeloma in 2026.
CAR-T or Bispecific Antibodies First? A Practical Sequencing Guide for Relapsed Multiple Myeloma in 2026
By Sean Maximillian Taasan, MD
CAR-T or bispecific antibodies first? A myeloma specialist breaks down the sequencing evidence, IMWG guidance, and practical factors that should guide treatment decisions in relapsed multiple myeloma in 2026.
CAR-T or Bispecific Antibodies First? A Practical Sequencing Guide for Relapsed Multiple Myeloma in 2026
By Sean Maximillian Taasan, MD
CAR-T or bispecific antibodies first? A myeloma specialist breaks down the sequencing evidence, IMWG guidance, and practical factors that should guide treatment decisions in relapsed multiple myeloma in 2026.
Belzutifan in 2026: Three Phase 3 Trials, Two Likely Approvals, and One Negative Surprise
By Scott Tykodi, MD, PhD
Three Phase 3 trials of belzutifan in clear cell RCC reported in 2026: two positive results poised for FDA approval, and one frontline surprise that leaves the current standard of care intact.
Belzutifan in 2026: Three Phase 3 Trials, Two Likely Approvals, and One Negative Surprise
By Scott Tykodi, MD, PhD
Three Phase 3 trials of belzutifan in clear cell RCC reported in 2026: two positive results poised for FDA approval, and one frontline surprise that leaves the current standard of care intact.
Belzutifan in 2026: Three Phase 3 Trials, Two Likely Approvals, and One Negative Surprise
By Scott Tykodi, MD, PhD
Three Phase 3 trials of belzutifan in clear cell RCC reported in 2026: two positive results poised for FDA approval, and one frontline surprise that leaves the current standard of care intact.
The Venetoclax Revolution in AML, and Its Limits in MDS: What the PARADIGM and VERONA Trials Mean for Practice
By By Bart L. Scott, MD
The PARADIGM and VERONA trials tell two very different stories about venetoclax in myeloid malignancies—a promising shift in AML treatment and a sobering setback in MDS. A leading expert breaks down both.
The Venetoclax Revolution in AML, and Its Limits in MDS: What the PARADIGM and VERONA Trials Mean for Practice
By By Bart L. Scott, MD
The PARADIGM and VERONA trials tell two very different stories about venetoclax in myeloid malignancies—a promising shift in AML treatment and a sobering setback in MDS. A leading expert breaks down both.
The Venetoclax Revolution in AML, and Its Limits in MDS: What the PARADIGM and VERONA Trials Mean for Practice
By By Bart L. Scott, MD
The PARADIGM and VERONA trials tell two very different stories about venetoclax in myeloid malignancies—a promising shift in AML treatment and a sobering setback in MDS. A leading expert breaks down both.